Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.HSAC · Entity 3632 | Director | May 09, 2019 | May 10, 2019 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2025 | July 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date May 09, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of Health Sciences Holdings, LLC. | 20,000 |
Reported balance
Holding disclosure · report date 2019-05-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2025 · Filed July 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Simran Investment Group | 415,346 |
Last balance in matching sequence
After 2025-06-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-06-18 · Grant · Acquired 30,000 · Balance 395,912 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026. Row 2 · 2025-06-18 · Grant · Acquired 19,434 · Balance 415,346 F3: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Non-Revocable Trust | 621,500 |
Reported balance
Holding disclosure · report date 2025-06-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 621,500 F4: The securities may be deemed to be beneficially owned by the reporting person and are held by a non-revocable trust for the benefit of the reporting person's children. The reporting person has no voting or investment power over all securities owned by the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026.
F3: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein.
F4: The securities may be deemed to be beneficially owned by the reporting person and are held by a non-revocable trust for the benefit of the reporting person's children. The reporting person has no voting or investment power over all securities owned by the trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jul 18, 2025 16:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 19,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026408 · form4.xml · nonDerivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 415,346 F3 · kind: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. F3 · shares: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2 · ownership.nature: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jul 18, 2025 16:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026408 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 395,912 F1 · kind: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F2 · ownership.nature: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026. Read SEC document |
| September 26, 2024 Filed Oct 29, 2024 16:58 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 303 | $0.00 Strike: $17.60 | $0.00 |
DisclosureSEC source: 0001140361-24-044546 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303 Underlying: Common Stock · 303 shares Expires 2034-09-26 F2 · derivative.exercise_date: This option represents a right to purchase a total of 303 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025. Read SEC document |
| September 26, 2024 Filed Oct 29, 2024 16:58 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 204 | $0.00 Strike: $17.60 | $0.00 |
DisclosureSEC source: 0001140361-24-044546 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204 Underlying: Common Stock · 204 shares Expires 2034-09-26 F1 · derivative.exercise_date: This option represents a right to purchase a total of 204 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 16:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 2,660 | $15.04 Strike: $22.86 | $40,006.40 |
DisclosureSEC source: 0001140361-24-030725 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,660 Underlying: Common Stock · 2,660 shares Expires 2034-06-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 2,660 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. This option was issued to the Reporting Person in lieu of director retainer fees of $40,000. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 16:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 23,944 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001140361-24-030725 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 Underlying: Common Stock · 23,944 shares Expires 2034-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:58 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 274,000 | $28.43 | $7,790,943.40 |
DisclosureSEC source: 0001140361-24-015103 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 365,912 F1 · ownership.nature: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed Jun 10, 2024 10:34 UTC Amendment | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 274,000 | $28.43 | $7,790,943.40 |
DisclosureSEC source: 0001140361-24-029438 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 365,912 F1 · ownership.nature: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 19:24 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 20,000 | $22.53 | $450,646.00 |
DisclosureSEC source: 0001140361-23-053713 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 1,296,497 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · kind: The shares were sold by the reporting person pursuant to an exemption to the Lock-Up Agreement in order to pay certain tax obligations. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. F3 · ownership.nature: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 21:02 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 4,677 | $21.14 | $98,863.83 |
DisclosureSEC source: 0001140361-23-046452 · form4.xml · nonDerivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 1,316,497 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · kind: The shares were sold by the reporting person pursuant to an exemption to the Lock-Up Agreement in order to pay certain tax obligations. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. F3 · ownership.nature: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 21:02 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 10,312 | $21.03 | $216,879.92 |
DisclosureSEC source: 0001140361-23-046452 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Simran Investment Group Disclosed balance after: 1,321,174 F1 · security: The shares beneficially owned by the reporting person are subject to a lock-up agreement dated September 12, 2023 (the "Lock-Up Agreement"). F2 · kind: The shares were sold by the reporting person pursuant to an exemption to the Lock-Up Agreement in order to pay certain tax obligations. Notwithstanding the sales reported on this Form 4, the securities beneficially owned by the reporting person remain subject to the terms of the Lock-Up Agreement. F3 · ownership.nature: The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 19:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 2,872 | $13.93 Strike: $21.56 | $40,006.96 |
DisclosureSEC source: 0001140361-23-031529 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,872 Underlying: Common Stock · 2,872 shares Expires 2033-06-22 F2 · derivative.exercise_date: This option represents a right to purchase a total of 2,872 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. This option was issued to the Reporting Person in lieu of director retainer fees of $40,000. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 19:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 25,850 | $0.00 Strike: $21.56 | $0.00 |
DisclosureSEC source: 0001140361-23-031529 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,850 Underlying: Common Stock · 25,850 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 21:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 5,876 | $6.80 Strike: $10.77 | $39,956.80 |
DisclosureSEC source: 0001140361-22-023151 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,876 Underlying: Common Stock · 5,876 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 5,876 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. This option was issued to the Reporting Person in lieu of director retainer fees of $40,000. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 21:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 47,745 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001140361-22-023151 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 Underlying: Common Stock · 47,745 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. Read SEC document |
| July 27, 2021 Filed Mar 9, 2022 16:53 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GiftCommon Stock | 621,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-008638 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Simran Investment Group Disclosed balance after: 674,901 F1 · shares: The shares were gifted by the reporting person to a nonrevocable trust for the benefit of the reporting person's children. The reporting person has no voting or investment power over all securities owned by the trust. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:52 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 400 | $47.13 | $18,850.00 |
DisclosureSEC source: 0001140361-21-021733 · form4.xml · nonDerivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Simran Investment Group Disclosed balance after: 1,296,401 F1 · ownership.nature: The securities reported herein were sold to cover certain tax liabilities. The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 16:52 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 34,685 | $46.85 | $1,624,843.10 |
DisclosureSEC source: 0001140361-21-021733 · form4.xml · nonDerivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Simran Investment Group Disclosed balance after: 1,296,801 F1 · ownership.nature: The securities reported herein were sold to cover certain tax liabilities. The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:13 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 1,529 | $29.42 Strike: $47.25 | $44,983.18 |
DisclosureSEC source: 0001140361-21-021302 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 Underlying: Common Stock · 1,529 shares Expires 2031-06-14 F2 · derivative.exercise_date: This option represents a right to purchase a total of 1,529 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022. This option was issued to the Reporting Person in lieu of director retainer fees of $45,000. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 20:13 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 12,236 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001140361-21-021302 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,236 Underlying: Common Stock · 12,236 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,236 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:38 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 3,206 | $12.16 Strike: $19.90 | $38,984.96 |
DisclosureSEC source: 0001140361-20-014239 · form4.xml · derivative · entry 3 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,206 Underlying: Common Stock · 3,206 shares Expires 2030-06-16 F3 · derivative.exercise_date: This option represents a right to purchase a total of 3,206 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. This option was issued to the Reporting Person in lieu of director retainer fees of $39,000. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:38 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 9,784 | $12.16 Strike: $19.90 | $118,973.44 |
DisclosureSEC source: 0001140361-20-014239 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,784 Underlying: Common Stock · 9,784 shares Expires 2030-06-16 F2 · derivative.exercise_date: This option represents a right to purchase a total of 9,784 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 21:38 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001140361-20-014239 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 18:35 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 4,666 | $9.96 Strike: $14.56 | $46,473.36 |
DisclosureSEC source: 0001140361-19-002009 · form4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Underlying: Common Stock · 4,666 shares Expires 2029-01-28 F2 · price: This option represents a right to purchase a total of 4,666 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on January 28, 2020. This option was issued to the Reporting Person in lieu of director retainer fees of $46,500. F2 · derivative.exercise_date: This option represents a right to purchase a total of 4,666 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on January 28, 2020. This option was issued to the Reporting Person in lieu of director retainer fees of $46,500. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 18:35 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001140361-19-002009 · form4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-01-28 F1 · derivative.exercise_date: This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on January 28, 2020. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:12 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 3,300 | $14.09 Strike: $18.75 | $46,497.00 |
DisclosureSEC source: 0000899243-18-009117 · doc4.xml · derivative · entry 2 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires 2028-03-29 F2 · price: This option represents a right to purchase a total of 3,300 shares of the Issuer's Common Stock, 1,116 of which will become fully vested and exercisable on March 29, 2019, with the remaining 2,184 shares vesting in equal monthly installments over the following two years. This option was issued to the Reporting Person in lieu of director retainer fees of $46,500. F2 · derivative.exercise_date: This option represents a right to purchase a total of 3,300 shares of the Issuer's Common Stock, 1,116 of which will become fully vested and exercisable on March 29, 2019, with the remaining 2,184 shares vesting in equal monthly installments over the following two years. This option was issued to the Reporting Person in lieu of director retainer fees of $46,500. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:12 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0000899243-18-009117 · doc4.xml · derivative · entry 1 Makker Gotham · CIK 0001726391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-29 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 13,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 26,664 shares vesting in equal monthly installments over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.